Revelation Biosciences (REVB) Competitors $2.97 +0.10 (+3.48%) Closing price 07/16/2025 04:00 PM EasternExtended Trading$3.04 +0.06 (+2.19%) As of 07:33 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock REVB vs. IMNN, RLYB, SYBX, AIMD, TXMD, TRIB, NKGN, FLGC, NEUP, and MEShould you be buying Revelation Biosciences stock or one of its competitors? The main competitors of Revelation Biosciences include Imunon (IMNN), Rallybio (RLYB), Synlogic (SYBX), Ainos (AIMD), TherapeuticsMD (TXMD), Trinity Biotech (TRIB), NKGen Biotech (NKGN), Flora Growth (FLGC), Neuphoria Therapeutics (NEUP), and 23andMe (ME). These companies are all part of the "pharmaceutical products" industry. Revelation Biosciences vs. Its Competitors Imunon Rallybio Synlogic Ainos TherapeuticsMD Trinity Biotech NKGen Biotech Flora Growth Neuphoria Therapeutics 23andMe Imunon (NASDAQ:IMNN) and Revelation Biosciences (NASDAQ:REVB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation. Is IMNN or REVB more profitable? Revelation Biosciences' return on equity of -299.46% beat Imunon's return on equity.Company Net Margins Return on Equity Return on Assets ImunonN/A -427.98% -175.03% Revelation Biosciences N/A -299.46%-115.36% Do institutionals and insiders believe in IMNN or REVB? 4.5% of Imunon shares are owned by institutional investors. Comparatively, 12.8% of Revelation Biosciences shares are owned by institutional investors. 6.0% of Imunon shares are owned by insiders. Comparatively, 2.3% of Revelation Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts rate IMNN or REVB? Imunon currently has a consensus target price of $15.50, indicating a potential upside of 3,042.10%. Given Imunon's stronger consensus rating and higher probable upside, equities analysts clearly believe Imunon is more favorable than Revelation Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Imunon 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.75Revelation Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has higher valuation and earnings, IMNN or REVB? Revelation Biosciences has lower revenue, but higher earnings than Imunon. Imunon is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImunon$500K17.30-$18.62M-$1.36-0.36Revelation BiosciencesN/AN/A-$15.04M-$307.86-0.01 Does the media refer more to IMNN or REVB? In the previous week, Revelation Biosciences had 3 more articles in the media than Imunon. MarketBeat recorded 6 mentions for Revelation Biosciences and 3 mentions for Imunon. Imunon's average media sentiment score of 0.80 beat Revelation Biosciences' score of -0.19 indicating that Imunon is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Imunon 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Revelation Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, IMNN or REVB? Imunon has a beta of 1.93, suggesting that its stock price is 93% more volatile than the S&P 500. Comparatively, Revelation Biosciences has a beta of -0.08, suggesting that its stock price is 108% less volatile than the S&P 500. SummaryImunon beats Revelation Biosciences on 9 of the 15 factors compared between the two stocks. Get Revelation Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for REVB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding REVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart REVB vs. The Competition Export to ExcelMetricRevelation BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.40M$2.90B$5.51B$9.31BDividend YieldN/A2.46%4.25%4.09%P/E Ratio-0.0120.3628.1919.69Price / SalesN/A299.07442.3499.85Price / CashN/A42.3835.5357.53Price / Book0.117.768.235.67Net Income-$15.04M-$55.11M$3.23B$257.51M7 Day Performance4.95%0.19%-0.57%-0.16%1 Month Performance25.32%10.80%6.66%9.89%1 Year Performance-96.62%-0.68%27.11%15.08% Revelation Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)REVBRevelation Biosciences0.9483 of 5 stars$2.97+3.5%N/A-96.7%$4.40MN/A-0.0110News CoverageHigh Trading VolumeIMNNImunon2.2943 of 5 stars$0.73-7.6%$15.50+2,023.3%-65.0%$13.86MN/A-0.5430Gap DownRLYBRallybio2.6632 of 5 stars$0.34+2.3%$10.00+2,837.7%-70.2%$13.85M$848K-0.3140News CoverageSYBXSynlogic1.1518 of 5 stars$1.19+0.8%N/A-3.2%$13.80M$10K-0.4780Positive NewsGap UpAIMDAinos1.5343 of 5 stars$3.30+0.3%N/A-25.5%$13.79M$20K-0.5140News CoverageTXMDTherapeuticsMD0.2639 of 5 stars$1.17-0.8%N/A-38.5%$13.66M$1.76M0.00420News CoveragePositive NewsTRIBTrinity Biotech1.1547 of 5 stars$0.73-2.0%N/A-73.6%$13.54M$61.56M-0.26480Positive NewsGap UpNKGNNKGen Biotech0.2647 of 5 stars$0.30flatN/A-71.0%$13.48MN/A-0.06N/ANews CoverageFLGCFlora Growth2.6271 of 5 stars$0.58-1.9%$4.00+584.9%-45.8%$13.43M$59.51M-0.60280Positive NewsNEUPNeuphoria Therapeutics2.2318 of 5 stars$7.16+0.4%$21.00+193.3%N/A$13.40M$10K0.00N/AME23andMeN/A$0.50-35.3%N/A-95.1%$13.36M$208.78M-0.03770Gap DownHigh Trading Volume Related Companies and Tools Related Companies Imunon Competitors Rallybio Competitors Synlogic Competitors Ainos Competitors TherapeuticsMD Competitors Trinity Biotech Competitors NKGen Biotech Competitors Flora Growth Competitors Neuphoria Therapeutics Competitors 23andMe Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:REVB) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revelation Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Revelation Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free REVB Stock Alerts